ES2689136T3 - Nuevos vectores de selección y métodos de selección de células hospedadoras eucariotas - Google Patents
Nuevos vectores de selección y métodos de selección de células hospedadoras eucariotas Download PDFInfo
- Publication number
- ES2689136T3 ES2689136T3 ES14753158.6T ES14753158T ES2689136T3 ES 2689136 T3 ES2689136 T3 ES 2689136T3 ES 14753158 T ES14753158 T ES 14753158T ES 2689136 T3 ES2689136 T3 ES 2689136T3
- Authority
- ES
- Spain
- Prior art keywords
- folate receptor
- folate
- mutated
- expression
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title description 7
- 238000010187 selection method Methods 0.000 title 1
- 108020005243 folate receptor Proteins 0.000 abstract description 82
- 102000006815 folate receptor Human genes 0.000 abstract description 81
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract description 70
- 235000019152 folic acid Nutrition 0.000 abstract description 59
- 239000011724 folic acid Substances 0.000 abstract description 53
- 108091033319 polynucleotide Proteins 0.000 abstract description 39
- 102000040430 polynucleotide Human genes 0.000 abstract description 39
- 239000002157 polynucleotide Substances 0.000 abstract description 39
- 229940014144 folate Drugs 0.000 abstract description 37
- 239000013604 expression vector Substances 0.000 abstract description 33
- 229920001184 polypeptide Polymers 0.000 abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 25
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 25
- 239000003550 marker Substances 0.000 abstract description 20
- 150000001413 amino acids Chemical group 0.000 abstract description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 9
- 235000001014 amino acid Nutrition 0.000 abstract description 9
- 239000012528 membrane Substances 0.000 abstract description 8
- 235000004279 alanine Nutrition 0.000 abstract description 7
- 230000007423 decrease Effects 0.000 abstract description 7
- 238000006467 substitution reaction Methods 0.000 abstract description 4
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 abstract description 3
- 230000014509 gene expression Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 31
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 16
- 229960000304 folic acid Drugs 0.000 description 16
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 150000002224 folic acids Chemical class 0.000 description 6
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 6
- 235000007635 levomefolic acid Nutrition 0.000 description 6
- 239000011578 levomefolic acid Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 102100035139 Folate receptor alpha Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000013643 reference control Substances 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 102100035143 Folate receptor gamma Human genes 0.000 description 2
- 101001023202 Homo sapiens Folate receptor gamma Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- BCCZFOXKKDTUTF-UHFFFAOYSA-N 5h-cyclopenta[g]quinazoline Chemical compound C1=NC=C2CC3=CC=CC3=CC2=N1 BCCZFOXKKDTUTF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- NVHRBQOZEMFKLD-CUYJMHBOSA-N BGC 945 Chemical compound C#CCN([C@@H]1C=2C=C3C(=O)N=C(NC3=CC=2CC1)CO)C1=CC=C(C(=O)N[C@@H](CCC(=O)N[C@H](CCC(O)=O)C(O)=O)C(O)=O)C=C1 NVHRBQOZEMFKLD-CUYJMHBOSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 102100035144 Folate receptor beta Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001023204 Homo sapiens Folate receptor beta Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229960005556 ONX-0801 Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 description 1
- 101100054110 Variola virus (isolate Human/India/Ind3/1967) A49L gene Proteins 0.000 description 1
- 102220479616 Voltage-dependent L-type calcium channel subunit beta-2_A49L_mutation Human genes 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000053180 human FOLR1 Human genes 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- -1 that is Chemical class 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860439P | 2013-07-31 | 2013-07-31 | |
| US201361860439P | 2013-07-31 | ||
| PCT/IB2014/063517 WO2015015419A1 (en) | 2013-07-31 | 2014-07-29 | Novel selection vectors and methods of selecting eukaryotic host cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2689136T3 true ES2689136T3 (es) | 2018-11-08 |
Family
ID=51383909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18179678T Active ES2920510T3 (es) | 2013-07-31 | 2014-07-29 | Vectores de selección novedosos y métodos para seleccionar células hospedadoras eucariotas |
| ES14753158.6T Active ES2689136T3 (es) | 2013-07-31 | 2014-07-29 | Nuevos vectores de selección y métodos de selección de células hospedadoras eucariotas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18179678T Active ES2920510T3 (es) | 2013-07-31 | 2014-07-29 | Vectores de selección novedosos y métodos para seleccionar células hospedadoras eucariotas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11807855B2 (enExample) |
| EP (3) | EP4095153A1 (enExample) |
| JP (1) | JP6576924B2 (enExample) |
| KR (1) | KR102288233B1 (enExample) |
| CN (2) | CN105593239B (enExample) |
| AU (1) | AU2014297966B2 (enExample) |
| BR (1) | BR112016001182A2 (enExample) |
| CA (1) | CA2918117C (enExample) |
| DK (2) | DK3412684T3 (enExample) |
| ES (2) | ES2920510T3 (enExample) |
| HU (1) | HUE058885T2 (enExample) |
| IL (1) | IL243352B (enExample) |
| LT (2) | LT3027646T (enExample) |
| MX (1) | MX369109B (enExample) |
| PL (2) | PL3027646T3 (enExample) |
| PT (2) | PT3027646T (enExample) |
| RU (1) | RU2716977C2 (enExample) |
| SG (1) | SG11201510625TA (enExample) |
| WO (1) | WO2015015419A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101707251B1 (ko) | 2009-02-27 | 2017-02-15 | 노파르티스 아게 | 2종의 선택 마커를 포함하는 발현 벡터 시스템 |
| KR102288233B1 (ko) | 2013-07-31 | 2021-08-10 | 노파르티스 아게 | 신규한 선택 벡터 및 진핵 숙주 세포의 선택 방법 |
| HUE069884T2 (hu) * | 2015-10-09 | 2025-04-28 | Genzyme Corp | Javított flare (áramlási citometriával csillapított reporter expresszió) technológia gyors tömeges válogatáshoz |
| EP3521435A1 (en) | 2018-02-06 | 2019-08-07 | Bayer AG | A high stringency selection system for protein expression in proline-auxotrophic cells |
| CN112673109A (zh) * | 2018-09-07 | 2021-04-16 | 免疫医疗有限责任公司 | 细胞选择方法 |
| US20220348632A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Nkg2d fusion proteins and uses thereof |
| CN116615462A (zh) | 2020-11-23 | 2023-08-18 | 诺华股份有限公司 | 抗体构建体的表达技术 |
| WO2022229854A1 (en) | 2021-04-29 | 2022-11-03 | Novartis Ag | Hypersialylating cells |
| US20250051758A1 (en) * | 2021-12-21 | 2025-02-13 | Absci Corporation | FolA Selection Assay to Identify Strains with Increased Soluble Target Protein Expression |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4771036A (en) | 1986-02-10 | 1988-09-13 | Trustees Of Columbia University In The City Of New York | Method and ophthalmic composition for the prevention and reversal of cataracts |
| JP2585532B2 (ja) | 1986-05-10 | 1997-02-26 | 三井東圧化学株式会社 | 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてｔ−ＰＡを生産する方法 |
| JP3150340B2 (ja) | 1990-11-13 | 2001-03-26 | イムネクス コーポレイション | 二機能選択可能融合遺伝子 |
| EP0724639B1 (en) | 1991-03-29 | 2001-01-31 | Genentech, Inc. | Methods for selection of recombinant host cells expressing high levels of a desired protein |
| JPH09500783A (ja) | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 |
| US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US6106825A (en) | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| FR2784030B1 (fr) | 1998-10-02 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine |
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| DE10256083A1 (de) | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| MXPA05009608A (es) * | 2003-03-11 | 2006-03-21 | Applied Research Systems | Vectores de expresion que comprenden el promotor mcmv ie2. |
| DE602005016218D1 (de) | 2004-01-30 | 2009-10-08 | Maxygen Aps | Gesteuertes überlesen von stopcodons |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| KR101328300B1 (ko) | 2006-02-21 | 2013-11-14 | 크로마제닉스 비.브이. | 고수준으로 단백질을 발현하는 숙주세포의 선택 |
| JP4870208B2 (ja) | 2006-05-17 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | ポリペプチド産生細胞 |
| PT2227549E (pt) | 2007-12-21 | 2015-10-08 | Novartis Ag | Sistema de seleção para cultura de células eucarióticas com base num gene de recetor de folato ligado à membrana |
| EP2227546B1 (en) | 2007-12-21 | 2016-05-04 | Novartis AG | Mammalian expression vector |
| RU2528858C2 (ru) | 2008-08-28 | 2014-09-20 | Новартис Аг | Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона |
| JP5748223B2 (ja) | 2008-09-10 | 2015-07-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子およびその使用 |
| MX2011009023A (es) | 2009-02-27 | 2011-09-28 | Novartis Ag | Metodos para seleccionar celulas eucarioticas que expresan una proteina heterologa. |
| KR101707251B1 (ko) | 2009-02-27 | 2017-02-15 | 노파르티스 아게 | 2종의 선택 마커를 포함하는 발현 벡터 시스템 |
| CN102030754B (zh) * | 2009-09-28 | 2013-07-10 | 中国科学院微生物研究所 | 非病毒载体及其制备方法与应用 |
| KR102288233B1 (ko) | 2013-07-31 | 2021-08-10 | 노파르티스 아게 | 신규한 선택 벡터 및 진핵 숙주 세포의 선택 방법 |
-
2014
- 2014-07-29 KR KR1020167002307A patent/KR102288233B1/ko active Active
- 2014-07-29 LT LTEP14753158.6T patent/LT3027646T/lt unknown
- 2014-07-29 PT PT14753158T patent/PT3027646T/pt unknown
- 2014-07-29 US US14/907,866 patent/US11807855B2/en active Active
- 2014-07-29 ES ES18179678T patent/ES2920510T3/es active Active
- 2014-07-29 CN CN201480054263.9A patent/CN105593239B/zh active Active
- 2014-07-29 DK DK18179678.0T patent/DK3412684T3/da active
- 2014-07-29 PL PL14753158T patent/PL3027646T3/pl unknown
- 2014-07-29 PT PT181796780T patent/PT3412684T/pt unknown
- 2014-07-29 JP JP2016530647A patent/JP6576924B2/ja active Active
- 2014-07-29 ES ES14753158.6T patent/ES2689136T3/es active Active
- 2014-07-29 EP EP22166577.1A patent/EP4095153A1/en not_active Withdrawn
- 2014-07-29 MX MX2016001396A patent/MX369109B/es active IP Right Grant
- 2014-07-29 CA CA2918117A patent/CA2918117C/en active Active
- 2014-07-29 PL PL18179678.0T patent/PL3412684T3/pl unknown
- 2014-07-29 HU HUE18179678A patent/HUE058885T2/hu unknown
- 2014-07-29 LT LTEP18179678.0T patent/LT3412684T/lt unknown
- 2014-07-29 WO PCT/IB2014/063517 patent/WO2015015419A1/en not_active Ceased
- 2014-07-29 EP EP18179678.0A patent/EP3412684B1/en active Active
- 2014-07-29 EP EP14753158.6A patent/EP3027646B1/en active Active
- 2014-07-29 RU RU2016106270A patent/RU2716977C2/ru active
- 2014-07-29 SG SG11201510625TA patent/SG11201510625TA/en unknown
- 2014-07-29 CN CN202010947233.8A patent/CN112029791A/zh active Pending
- 2014-07-29 DK DK14753158.6T patent/DK3027646T3/en active
- 2014-07-29 BR BR112016001182A patent/BR112016001182A2/pt not_active Application Discontinuation
- 2014-07-29 AU AU2014297966A patent/AU2014297966B2/en active Active
-
2015
- 2015-12-24 IL IL243352A patent/IL243352B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2689136T3 (es) | Nuevos vectores de selección y métodos de selección de células hospedadoras eucariotas | |
| JP7754721B2 (ja) | 標的ｒｎａを編集するための機能性領域を付加したアンチセンス型ガイドｒｎａ | |
| ES2835051T3 (es) | Secuencias de UTR mínimas novedosas | |
| JP2023025108A (ja) | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 | |
| JP7486206B2 (ja) | 人工的に構築されたｒｎａ編集酵素による部位特異的ｒｎａ編集および関連使用 | |
| CN101903526B (zh) | 有机化合物 | |
| Precious et al. | Inducible expression of the P, V, and NP genes of the paramyxovirus simian virus 5 in cell lines and an examination of NP-P and NP-V interactions | |
| ES2587630T3 (es) | Sistema de vector de expresión que comprende dos marcadores de selección | |
| CN105331608A (zh) | 脑膜炎双球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用 | |
| CN102227501A (zh) | 基因治疗载体和胞嘧啶脱氨酶 | |
| JP2019517815A5 (enExample) | ||
| CN111892661B (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| JP5513467B2 (ja) | リンパ球系・血球系細胞へ遺伝子導入するためのプロモーターおよびその利用方法 | |
| EP4493197A2 (en) | Compositions and methods for improved protein translation from recombinant circular rnas | |
| CZ20003807A3 (cs) | DNA konstrukt, izolovaná molekula nukleové kyseliny, homologně rekombinantní buňka a její použití, způsob pozměnění exprese endogenního G-CSF genu a způsob produkce G-CSF | |
| AR016262A1 (es) | Una construccion de adn que altera la expresion de un gen pshbeta endogeno, una celula homologamente recombinante, un metodo para alterar la expresion dela fshbeta endogeno en la celula de un mamifero, uso de dicha celula para la manufactura de un medicamento, un metodo para producir fshbeta y una m | |
| CN118324864B (zh) | 靶向人源多药耐药相关蛋白mrp5的肽类抑制剂 | |
| CN114380918B (zh) | 一种目标rna单碱基编辑的系统和方法 | |
| JP2007527200A (ja) | ヒトａｎｔのアイソフォームの発現の調節方法 | |
| ES2330784T3 (es) | Vectores que comprenden nuevos elementos reguladores. | |
| WO2022269349A2 (en) | Compositions and methods for modulating expression of genes | |
| Almeida et al. | Micropia transposable element occurrence in Drosophila species of the saltans group | |
| US20120039858A1 (en) | Methods and compositions for inhibiting propagation of viruses using recombinant tetherin constructs | |
| US20170319649A1 (en) | Novel peptide activator of cyclin c-dependent kinase 8 (cdk8) | |
| WO2021046451A1 (en) | Compositions and methods for dhfr tunable protein regulation |